Immunological Features of EGFR-mutant Non-small Cell Lung Cancer and Clinical Practice: a Narrative Review

Overview

Journal J Natl Cancer Cent

Specialty Oncology

Date 2024 Dec 30

PMID 39735443

Authors

Yi Dong

Liaqat Khan

Yi Yao

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced driver-negative non-small cell lung cancer (NSCLC). However, targeted therapy remains the preferred treatment for advanced driver-positive NSCLC, including cases with epidermal growth factor receptor (EGFR) mutations. Considering the variability in EGFR-mutant NSCLC, including expression levels of programmed cell death ligand 1 (PD-L1), tumor mutation burden (TMB), and other immunological features, the application of immunotherapy in this group is still a subject of investigation. Therefore, we have summarized and analyzed the immunological characteristics and regulatory mechanisms of different EGFR mutations in NSCLC, as well as the current clinical application of immunotherapy in the EGFR-mutant population, to provide a reference for future research.

References

Yang J, Lee D, Lee J, Fan Y, de Marinis F, Iwama E . Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, -Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer. J Clin Oncol. 2024; 42(34):4029-4039. PMC: 11608596. DOI: 10.1200/JCO.23.02747. View

Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T . Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. J Thorac Oncol. 2020; 16(2):205-215. DOI: 10.1016/j.jtho.2020.10.006. View

Gettinger S, Choi J, Mani N, Sanmamed M, Datar I, Sowell R . A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun. 2018; 9(1):3196. PMC: 6086912. DOI: 10.1038/s41467-018-05032-8. View

Chandrasekaran S, Sasaki M, Scharer C, Kissick H, Patterson D, Magliocca K . Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. Mol Cancer Res. 2019; 17(12):2395-2409. PMC: 7339488. DOI: 10.1158/1541-7786.MCR-19-0545. View

Togashi Y, Shitara K, Nishikawa H . Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019; 16(6):356-371. DOI: 10.1038/s41571-019-0175-7. View

Shi C, Wang Y, Xue J, Zhou X . Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. Front Immunol. 2022; 13:940288. PMC: 9353115. DOI: 10.3389/fimmu.2022.940288. View

Patel S, Nilsson M, Le X, Cascone T, Jain R, Heymach J . Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. Clin Cancer Res. 2022; 29(1):30-39. PMC: 10274152. DOI: 10.1158/1078-0432.CCR-22-1366. View

Gubens M, Sequist L, Stevenson J, Powell S, Villaruz L, Gadgeel S . Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer. 2019; 130:59-66. DOI: 10.1016/j.lungcan.2018.12.015. View

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

10.

Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim H . Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. J Clin Oncol. 2024; 42(11):1252-1264. PMC: 11095864. DOI: 10.1200/JCO.23.01017. View

11.

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

12.

Kumagai S, Koyama S, Nishikawa H . Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer. 2021; 21(3):181-197. DOI: 10.1038/s41568-020-00322-0. View

13.

Gong Z, Chen J, Cheng J, Sun C, Jia Q, Diao X . Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma. Clin Lung Cancer. 2018; 19(5):e551-e558. DOI: 10.1016/j.cllc.2018.03.011. View

14.

Pollack B . EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?. Oncoimmunology. 2012; 1(1):71-74. PMC: 3376950. DOI: 10.4161/onci.1.1.18073. View

15.

Gainor J, Shaw A, Sequist L, Fu X, Azzoli C, Piotrowska Z . EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016; 22(18):4585-93. PMC: 5026567. DOI: 10.1158/1078-0432.CCR-15-3101. View

16.

Koh Y, Park B, Jung S, Han J, Haam S, Lee H . Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma. Front Immunol. 2023; 14:1137880. PMC: 10079979. DOI: 10.3389/fimmu.2023.1137880. View

17.

Vantourout P, Willcox C, Turner A, Swanson C, Haque Y, Sobolev O . Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway. Sci Transl Med. 2014; 6(231):231ra49. PMC: 3998197. DOI: 10.1126/scitranslmed.3007579. View

18.

Levantini E, Maroni G, Del Re M, Tenen D . EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022; 85:253-275. DOI: 10.1016/j.semcancer.2022.04.002. View

19.

Passarelli A, Aieta M, Sgambato A, Gridelli C . Targeting Immunometabolism Mediated by CD73 Pathway in -Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance. Front Immunol. 2020; 11:1479. PMC: 7371983. DOI: 10.3389/fimmu.2020.01479. View

20.

Feng P, Chen K, Huang Y, Luo C, Wu S, Chen T . Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma. J Thorac Oncol. 2018; 13(7):958-967. DOI: 10.1016/j.jtho.2018.03.032. View